z-logo
open-access-imgOpen Access
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
Author(s) -
F.-J. Schmitz,
Ad C. Fluit,
Marc Lückefahr,
Birgit Engler,
B. Hofmann,
J. Verhoef,
HansPeter Heinz,
U. Hadding,
Michael E. Jones
Publication year - 1998
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/42.6.807
Subject(s) - sparfloxacin , moxifloxacin , ciprofloxacin , efflux , microbiology and biotechnology , ofloxacin , staphylococcus aureus , multiple drug resistance , antibacterial agent , antibiotics , biology , pharmacology , bacteria , biochemistry , genetics
In Staphylococcus aureus, in addition to mutations in the grl and gyr gene loci, multidrug efflux pumps like NorA contribute to decreased fluoroquinolone susceptibility. Efflux pumps can be inhibited by the plant alkaloid reserpine, which, at 20 mg/L, reduced sparfloxacin, moxifloxacin and ciprofloxacin IC50s and MICs by up to four-fold in 11, 21 and 48 of the 102 unrelated clinical isolates tested, respectively. The effect was less pronounced with the hydrophobic drugs sparfloxacin and moxifloxacin than with the hydrophilic drug ciprofloxacin and was stable in all 25 clonally related isolates tested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom